by Clinical Neuropsychologist | Wednesday, February 12, 2025 | Dementia
Abstract INTRODUCTION There is an unmet need for tools to quantify dementia risk during its multi-decade preclinical/prodromal phase, given that current biomarkers predict risk over shorter follow-up periods and are specific to Alzheimer’s disease. METHODS Using...
by Clinical Neuropsychologist | Wednesday, February 12, 2025 | Dementia
Abstract INTRODUCTION The presence of psychosis in Alzheimer’s disease (AD) is suggested to be associated with distinct molecular and neuropathological profiles in the brain. METHODS We assessed brain DNA methylation in AD donors with psychosis (AD+P) and...
by Clinical Neuropsychologist | Wednesday, February 12, 2025 | Dementia
Abstract INTRODUCTION Alzheimer’s disease (AD) diagnosis centers on cognitive impairment despite other early indicators like neuropsychiatric symptoms (NPSs) and amyloid beta (Aβ) accumulation. This study examined how cognition, NPS, and Aβ changes are...
by Clinical Neuropsychologist | Wednesday, February 12, 2025 | Dementia
Abstract The characteristic events in neurodegenerative diseases (NDDs) encompass protein misfolding, aggregation, accumulation, and their related cellular dysfunction, synaptic function loss. While distinct proteins are implicated in the pathological processes of...
by Clinical Neuropsychologist | Wednesday, February 12, 2025 | Dementia
Abstract INTRODUCTION Blood–brain barrier (BBB) breakdown is essential in Alzheimer’s disease (AD) and dementia with Lewy bodies (DLB), whereas the variability in BBB permeability to water and contrast agent is less clear. METHODS We investigated BBB...
